Kratom Research Institute

News · 2026-07-01

DEA 7-OH Temporary Scheduling Explained: Which Products Are Covered, What Happens Next

Source: Addiction Center

Why it matters

The DEA's July 1 announcement is the most significant federal action affecting kratom-adjacent products in years. Understanding exactly what is scheduled, what remains legal, and what timeline applies is critical for consumers, retailers, clinicians, and policymakers navigating the transition.

The big picture

The FDA recommended scheduling concentrated 7-OH products as Schedule I in July 2025. Following that recommendation, the DEA on July 1, 2026, announced its intent to issue a temporary scheduling order covering products meeting specific 7-OH concentration thresholds. The action explicitly does not target natural kratom leaf. The DEA has targeted the rapidly expanding market for enhanced 7-OH products — gummies, shots, tablets — which federal officials have compared to over-the-counter opioids accessible without any safeguards.

Key findings

What they say

The FDA cautioned that "many of these products contain inconsistent concentrations, inaccurate labeling, and undisclosed ingredients, making it difficult for consumers to know how much active drug they are ingesting."

Bottom line

**The DEA's 7-OH temporary scheduling targets concentrated products above specific thresholds — not natural kratom leaf — but retailers and consumers have a narrow window before formal Schedule I restrictions take effect, potentially as early as August 5.**